Q1 Earnings Estimate for BRTX Issued By Roth Capital

BioRestorative Therapies, Inc. (NASDAQ:BRTX) – Analysts at Roth Capital issued their Q1 2025 earnings per share (EPS) estimates for shares of BioRestorative Therapies in a note issued to investors on Tuesday, November 5th. Roth Capital analyst J. Aschoff expects that the company will post earnings of ($0.34) per share for the quarter. The consensus estimate for BioRestorative Therapies’ current full-year earnings is ($1.83) per share. Roth Capital also issued estimates for BioRestorative Therapies’ Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.27) EPS, FY2027 earnings at $2.47 EPS and FY2028 earnings at $5.43 EPS.

Separately, Roth Mkm raised their price target on BioRestorative Therapies from $15.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th.

BioRestorative Therapies Trading Up 6.5 %

NASDAQ:BRTX opened at $1.65 on Wednesday. The company has a market cap of $11.42 million, a PE ratio of -0.81 and a beta of 63.40. The company has a 50 day simple moving average of $1.63 and a two-hundred day simple moving average of $1.58. BioRestorative Therapies has a 12 month low of $1.03 and a 12 month high of $3.67.

BioRestorative Therapies (NASDAQ:BRTX) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.06. The firm had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.03 million. BioRestorative Therapies had a negative net margin of 6,898.28% and a negative return on equity of 107.65%. During the same period in the previous year, the company earned ($0.77) earnings per share.

About BioRestorative Therapies

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.